RE:RE:RE:Novartis Sells Shares Back to Roche for $20.7 BillionNovartis will potentially receive another $US21.6 Billion for the sale of its generic unit Sandoz in addition to the US$20.7 Billion received from Roche for the repurchase of Roche's shares.
In the recent news, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase Novartis' generics outfit for $21.6 billion.
"The price would make it the largest pharma deal of the year. EQT and the Struengmanns, who provided the investment power behind BioNTech, have attracted interest from other private equity investors to join the group."
https://www.fiercepharma.com/pharma/novartis-may-have-a-buyer-for-generics-unit-sandoz-at-21-6-billion-report